GET THE APP

Regulation of Bile Acids by an NTCP Inhibitor is Promising for the Treatment of Nonalcoholic Steatohepatitis | Abstract
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 20 3868 9735

Abstract

Regulation of Bile Acids by an NTCP Inhibitor is Promising for the Treatment of Nonalcoholic Steatohepatitis

Cuili Fan, Hongli Liu* and Jian Wu*

The beneficial effects of Hepalatide, an inhibitor of sodium taurocholate cotransporting polypeptide (NTCP), on the progression of nonalcoholic steato hepatitis was previously validated in mice. The underlying mechanismsare presumably associated with the profile changes of bile acids, which are natural agonistsfor FXR and TGR5receptors. In this short communication, the profile of bile acids and the metabolic changes in the liver or peripheral tissues were analyzed. It is our anticipation that using NTCP inhibitors, such as Hepalatide for the nonalcoholic steatohepatitis would be a clinically-applicable strategy

Published Date: 2020-07-01; Received Date: 2020-06-11